Vasoactive Peptide Pharmacology

Correct Answer

B — Calcitonin gene-related peptide receptor

Rationale

Gepants are classified as small-molecule calcitonin gene-related peptide receptor antagonists. Members of the class include ubrogepant, rimegepant, and atogepant. Serotonin 1B/1D receptor agonism is the mechanism of triptans — the prior generation of migraine-specific acute treatments. Endothelin ETA receptor antagonists such as bosentan and ambrisentan are used in pulmonary arterial hypertension. Vasopressin V2 receptor antagonists are the vaptans, used for hyponatremia.

Correct Answer

D — Monoclonal antibody targeting the calcitonin gene-related peptide receptor, specifically the RAMP1 subunit

Rationale

Erenumab is a monoclonal antibody that targets the calcitonin gene-related peptide receptor — specifically its receptor activity-modifying protein 1 subunit. This receptor-targeting mechanism distinguishes erenumab from the other three approved anti-calcitonin gene-related peptide monoclonal antibodies, which all target the calcitonin gene-related peptide peptide itself. Small-molecule calcitonin gene-related peptide receptor antagonists are the gepants — ubrogepant, rimegepant, and atogepant. Serotonin 1B/1D receptor agonism is the mechanism of triptans, a different drug class entirely.

Correct Answer

A — Acute migraine treatment only

Rationale

Ubrogepant is classified as a gepant approved for acute treatment of migraine only — it is taken at headache onset and has no approved preventive indication. Among the three approved gepants, the indications differ: ubrogepant is acute only, atogepant is preventive only, and rimegepant has dual approval for both acute and preventive treatment. No gepant is approved for cluster headache prevention. Knowing these indication subclasses distinguishes the three gepants at a classification vocabulary level.

Correct Answer

C — Rimegepant

Rationale

Rimegepant is the only gepant classified as having dual approval — it can be used for acute treatment of migraine when taken at headache onset, and for preventive treatment when taken on an every-other-day schedule to reduce monthly migraine days. Ubrogepant is approved for acute treatment only. Atogepant is approved for preventive treatment only. Erenumab is a monoclonal antibody, not a gepant, and is approved for preventive use only. Rimegepant's dual-indication classification makes it unique within the gepant class.

Correct Answer

B — The calcitonin gene-related peptide peptide itself, binding it directly and preventing receptor activation

Rationale

Fremanezumab, galcanezumab, and eptinezumab are all classified as monoclonal antibodies that target the calcitonin gene-related peptide peptide directly. By binding the peptide, they prevent it from reaching and activating the calcitonin gene-related peptide receptor. This peptide-targeting classification distinguishes all three from erenumab, the only antibody in the class that targets the receptor itself — specifically its receptor activity-modifying protein 1 subunit. Monoclonal antibodies cannot enter neurons to reduce peptide synthesis; they act extracellularly by binding the secreted peptide.

Correct Answer

D — Preventive migraine treatment only

Rationale

Atogepant is classified as a gepant approved exclusively for preventive migraine treatment. It is taken daily or every other day to reduce monthly migraine frequency and has no approved indication for acute migraine treatment. This contrasts with ubrogepant, which is acute only, and rimegepant, which has dual approval for both acute and preventive use. Among the three approved gepants, atogepant and ubrogepant each have a single indication, while rimegepant is the only one with dual-indication classification.

Correct Answer

C — Calcitonin gene-related peptide produces meningeal vasodilation and neurogenic inflammation, sensitizing local pain afferents and second-order neurons in the trigeminal nucleus caudalis

Rationale

During a migraine attack, calcitonin gene-related peptide is released in large quantities from activated trigeminal sensory nerve terminals innervating the meningeal blood vessels. It produces three effects that sustain and amplify migraine pain: potent vasodilation of the meningeal arteries, which distends vessel walls and stimulates pain afferents; neurogenic inflammation in the dura, including increased vascular permeability, plasma protein extravasation, and mast cell degranulation; and central sensitization through action on the trigeminal nucleus caudalis, contributing to allodynia in established migraine. Calcitonin gene-related peptide acts as a vasodilator, not a vasoconstrictor — the vasoconstrictive mechanism belongs to triptans acting on serotonin 1B/1D receptors. Calcitonin gene-related peptide does not cross the blood-brain barrier in meaningful amounts and does not initiate cortical spreading depression directly.

Correct Answer

A — Gepants block the calcitonin gene-related peptide receptor without activating serotonin 1B receptors, producing no vasoconstriction of coronary or cerebrovascular smooth muscle

Rationale

Triptans are serotonin 1B/1D receptor agonists. Serotonin 1B receptors are expressed on coronary and cerebrovascular smooth muscle, and triptan-mediated activation produces vasoconstriction at these sites — creating the risk of myocardial ischemia or stroke in patients with pre-existing coronary artery disease or cerebrovascular disease. Gepants act exclusively by blocking the calcitonin gene-related peptide receptor, a mechanistically distinct target that is not a vasoconstrictor pathway. Because gepants do not activate serotonin 1B receptors, they produce no coronary or cerebrovascular vasoconstriction and can be used safely in patients for whom triptans are contraindicated. The cardiovascular safety advantage is mechanistic, not pharmacokinetic.

Correct Answer

D — The receptor is a heterodimer requiring non-covalent co-expression of the calcitonin receptor-like receptor and receptor activity-modifying protein 1; neither component alone forms a functional calcitonin gene-related peptide receptor

Rationale

The calcitonin gene-related peptide receptor is unusual in that it requires two distinct proteins for function. The calcitonin receptor-like receptor is a seven-transmembrane G protein-coupled receptor that cannot bind calcitonin gene-related peptide or signal efficiently on its own. Receptor activity-modifying protein 1 is a single-pass transmembrane protein that acts as a chaperone, enabling cell surface expression and conferring ligand binding specificity for calcitonin gene-related peptide. Only when both are co-expressed does a functional receptor form. This two-component architecture is why erenumab — the only receptor-targeting antibody in the anti-calcitonin gene-related peptide class — targets the receptor activity-modifying protein 1 subunit specifically. Gepants must accommodate both components to block receptor activation.

Correct Answer

C — Erenumab targets the calcitonin gene-related peptide receptor (RAMP1 subunit), while fremanezumab, galcanezumab, and eptinezumab bind the calcitonin gene-related peptide peptide itself

Rationale

Erenumab is the only anti-calcitonin gene-related peptide monoclonal antibody that targets the receptor rather than the peptide. It binds the receptor activity-modifying protein 1 subunit of the calcitonin gene-related peptide receptor complex, blocking the receptor from being activated by calcitonin gene-related peptide. Fremanezumab, galcanezumab, and eptinezumab all bind the calcitonin gene-related peptide peptide directly, sequestering it before it reaches the receptor. Both approaches reduce calcitonin gene-related peptide signaling and produce similar preventive efficacy — the clinical outcomes of receptor-targeting versus peptide-targeting have not been shown to differ meaningfully in practice. All four antibodies are approved for preventive migraine treatment only; none has acute efficacy.

Correct Answer

B — The long half-life of immunoglobulin G antibodies produces gradual, sustained reduction in calcitonin gene-related peptide signaling suited to prevention, but does not generate the rapid onset of action needed to abort an acute migraine attack

Rationale

Anti-calcitonin gene-related peptide monoclonal antibodies are immunoglobulin G molecules with plasma half-lives of approximately 28 days. This long half-life allows monthly or quarterly dosing and produces sustained, gradual reduction in calcitonin gene-related peptide activity — ideal for prevention of future attacks. However, the slow pharmacokinetics mean that a single dose given at the onset of a migraine attack does not produce rapid enough calcitonin gene-related peptide receptor blockade to abort the acute episode. Gepants, by contrast, are small molecules with rapid oral absorption and short half-lives suitable for acute dosing. The blood-brain barrier argument is a common misconception; anti-calcitonin gene-related peptide antibodies act primarily at peripheral sites on the meningeal vasculature and trigeminal endings outside the blood-brain barrier, and peripheral calcitonin gene-related peptide blockade is sufficient for both preventive and acute efficacy — the issue is kinetics, not anatomy.

Correct Answer

D — Erenumab blocks calcitonin gene-related peptide receptors in the enteric nervous system, where calcitonin gene-related peptide normally promotes intestinal motility; the peptide-targeting antibodies bind the peptide but may leave some receptor-mediated enteric signaling intact

Rationale

Calcitonin gene-related peptide receptors are expressed in the enteric nervous system, where calcitonin gene-related peptide normally contributes to the regulation of intestinal motility. Erenumab, as a receptor-blocking antibody, occupies the receptor activity-modifying protein 1 subunit and prevents any calcitonin gene-related peptide — regardless of source — from signaling through these enteric receptors. This receptor blockade impairs calcitonin gene-related peptide-mediated promotion of gut motility, resulting in constipation. Fremanezumab, galcanezumab, and eptinezumab bind and sequester the calcitonin gene-related peptide peptide itself, which may not fully eliminate receptor activation in tissues with local peptide production or with peptide concentrations exceeding antibody binding capacity. Erenumab's constipation occurs in approximately 3 to 4 percent of patients — rare but distinctive and clinically noted in trials. Erenumab is not eliminated through the gastrointestinal tract and does not cross-react with serotonin receptors.

Correct Answer

A — Ketoconazole is a strong cytochrome P450 3A4 inhibitor and gepants are cytochrome P450 3A4 substrates; inhibition raises gepant plasma levels, requiring dose reduction or avoidance of the combination

Rationale

All gepants are substrates of cytochrome P450 3A4 — the primary hepatic enzyme responsible for their metabolism. Ketoconazole is a potent cytochrome P450 3A4 inhibitor. When ketoconazole inhibits cytochrome P450 3A4, gepant metabolism is slowed and plasma gepant levels rise, potentially increasing adverse effects. Dose reduction or avoidance of the combination is appropriate. The reverse situation — a strong cytochrome P450 3A4 inducer such as rifampin — accelerates gepant metabolism, lowers plasma levels, and reduces preventive efficacy. These interactions are pharmacokinetic and enzyme-mediated, not pharmacodynamic. Gepants do not share renal elimination as a clinically relevant pathway for this class of drug interaction.

Correct Answer

B — Intravenous infusion of calcitonin gene-related peptide reliably provokes migraine-like headache in migraine-prone individuals but not in healthy controls

Rationale

Establishing that calcitonin gene-related peptide is merely elevated during migraine (correlation) versus that it actually causes migraine pain (causation) requires a pharmacological provocation experiment. Intravenous calcitonin gene-related peptide infusion reliably triggers migraine-like headache in individuals who suffer from migraine but does not provoke headache in healthy controls. This provocation experiment demonstrates that calcitonin gene-related peptide, when present in sufficient concentrations, can initiate the migraine cascade — proving it is an active mediator rather than a secondary release product of pain. The normalization of calcitonin gene-related peptide levels after triptan treatment shows correlation with treatment response but does not prove causation. Elevated levels in other pain conditions would actually weaken, not strengthen, the migraine-specific causal argument. Messenger ribonucleic acid expression confirms biosynthesis but not physiological relevance.

Correct Answer

B — Gepants, which block the calcitonin gene-related peptide receptor and abort acute migraine without activating serotonin 1B receptors or producing vasoconstriction

Rationale

Sumatriptan is a serotonin 1B/1D receptor agonist. Serotonin 1B receptors on coronary smooth muscle mediate vasoconstriction, which is why triptans are contraindicated in patients with ischemic heart disease, prior stroke, uncontrolled hypertension, and hemiplegic or basilar migraine. Gepants — ubrogepant or rimegepant for acute use — block the calcitonin gene-related peptide receptor through a mechanistically distinct pathway that produces no vasoconstriction and no serotonin receptor activation. This makes them the appropriate migraine-specific acute treatment in this patient. Anti-calcitonin gene-related peptide monoclonal antibodies are preventive only and have no acute efficacy. Ergot alkaloids produce non-selective vasoconstriction and are even more contraindicated than triptans in patients with coronary artery disease. Endothelin receptor antagonists treat pulmonary arterial hypertension and have no role in migraine management.

Correct Answer

D — Erenumab; as the only receptor-blocking antibody in the class, it blocks calcitonin gene-related peptide receptors in the enteric nervous system where calcitonin gene-related peptide normally promotes intestinal motility

Rationale

Constipation occurring in approximately 3 to 4 percent of patients is a distinctive adverse effect of erenumab not observed with the peptide-targeting antibodies. Erenumab is the only anti-calcitonin gene-related peptide monoclonal antibody that targets the receptor — specifically the receptor activity-modifying protein 1 subunit — rather than the peptide. Calcitonin gene-related peptide receptors are expressed in the enteric nervous system, where calcitonin gene-related peptide contributes to the regulation of intestinal smooth muscle activity and motility. By blocking receptor activation throughout the body including the gut, erenumab impairs calcitonin gene-related peptide-mediated promotion of intestinal motility, resulting in constipation. Fremanezumab, galcanezumab, and eptinezumab bind and sequester the calcitonin gene-related peptide peptide without fully eliminating receptor-mediated enteric signaling, and do not carry this adverse effect signal.

Correct Answer

A — Regular every-other-day dosing maintains sustained partial blockade of calcitonin gene-related peptide receptors, reducing the baseline level of calcitonin gene-related peptide-mediated sensitization that lowers the threshold for migraine triggering

Rationale

Rimegepant is the only gepant with dual approval for both acute and preventive migraine treatment. When taken every other day on a regular schedule rather than only at headache onset, rimegepant maintains ongoing partial blockade of calcitonin gene-related peptide receptors in the trigeminal and meningeal system. This sustained receptor blockade reduces the background level of calcitonin gene-related peptide-mediated sensitization and vasodilatory tone that makes the trigeminovascular system more susceptible to migraine triggers. By keeping calcitonin gene-related peptide receptor activation tonically reduced, rimegepant raises the threshold required to initiate a migraine attack and reduces monthly migraine days. This is pharmacologically analogous to how daily preventive medications such as topiramate or beta blockers work — by altering baseline neuronal excitability — rather than by treating attacks once they begin. Rimegepant does not enter neurons to suppress peptide synthesis and does not work through receptor desensitization.

Correct Answer

C — There is no strong evidence for cross-resistance within the anti-calcitonin gene-related peptide monoclonal antibody class; patients who do not respond to one agent in the class sometimes respond to another, making a trial of a third agent reasonable before abandoning the class

Rationale

Within the anti-calcitonin gene-related peptide monoclonal antibody class, the clinical evidence does not support a model of complete cross-resistance — that is, failure of one antibody does not reliably predict failure of all others in the class. Individual patient responses appear to vary across agents even when the mechanism is broadly similar, possibly due to differences in antibody affinity, epitope binding, tissue distribution, or pharmacokinetic profiles. Current clinical guidance supports trying a second or third agent within the class before declaring the calcitonin gene-related peptide pathway unresponsive in a given patient. This is a pragmatic recommendation based on observed clinical practice rather than a mechanistic certainty. If two or more antibodies fail, transitioning to a non-calcitonin gene-related peptide preventive — topiramate, valproate, beta blockers, amitriptyline — or combining with a gepant is reasonable. Galcanezumab is administered monthly by subcutaneous injection, not quarterly.